Study of a new virus therapy for high-risk bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of high-grade bladder cancer (called non-muscle-invasive, or NMIBC) that is at high risk of coming back or spreading.
- If you have never had BCG treatment, you may be in the first group. If you have had BCG treatment before, you may be in another group.
- All visible tumors and abnormal tissue must have been removed from your bladder within the last 3 months.
- Your kidneys, liver, and blood cells should be working well enough for the trial.
- You cannot have a very weak immune system, be pregnant or breastfeeding, or have a history of cancer that has spread to the muscle or beyond.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with bladder cancer that has not responded to BCG therapy. The study tests a new virus-based treatment (called cretostimogene grenadenorepvec) that is given directly into the bladder to help fight the cancer cells.
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
This trial tests a new drug, Cretostimogene, for people with a type of bladder cancer that hasn't spread into the muscle layer (non-muscle invasive) and has not responded to standard BCG treatment. The goal is to see if this drug can help control the cancer and avoid the need for bladder removal surgery.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Hear when a new High Risk Non-muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.